Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 2/20 | 0.85 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.85 |
| ▸ | EP300 | Q09472 | 4/20 | 0.84 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.84 |
| ▸ | AURKA | O14965 | 2/20 | 0.84 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.84 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.79 |
| ▸ | NAA40 | Q86UY6 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30991360 | 1.00 | CHAT (0.85) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL30361785 | 1.00 | CHAT (0.85) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL20815907 | 1.00 | CHAT (0.85) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL26700227 | 0.96 | EP300 (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL28803301 | 0.96 | EP300 (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL28670397 | 0.95 | CHAT (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL29366032 | 0.95 | NAA50 (0.84) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL28017929 | 0.94 | EP300 (0.84) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL2112268 | 0.94 | CHAT (0.83) | CHATNAA50EP300KAT5AURKA | |
| SCHEMBL18608119 | 0.94 | CHAT (0.87) | CHATNAA50EP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008884-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-01-10 | — | — | US | claimed |
| US-20160250249-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2016-09-01 | — | — | US | claimed |
| EP-3052133-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2016-08-10 | — | — | EP | claimed |
| WO-2015049365-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-04-09 | — | — | WO | claimed |
| US-11040052-B2 | Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-06-22 | — | — | US | disclosed |
| US-20210030703-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-02-04 | — | — | US | disclosed |
| EP-3765085-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | Université de Paris (FR) | 2021-01-20 | — | — | EP | disclosed |
| CN-112218658-A | Use of caloric restriction mimetics for enhancing chemoimmunotherapy for cancer treatment | 国家健康科学研究所 | 2021-01-12 | — | — | CN | disclosed |
| WO-2020182615-A1 | CRYSTAL STRUCTURE OF ATP CITRATE LYASE AND USES THEREOF | VIB VZW (BE) | 2020-09-17 | — | — | WO | disclosed |
| WO-2019175113-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-09-19 | — | — | WO | disclosed |
| US-20190008884-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-01-10 | — | — | US | disclosed |
| WO-2016207867-A1 | NAT8L AND N-ACETYLASPARTATE IN CANCER | UNIVERSITÉ DU LUXEMBOURG (LU) | 2016-12-29 | — | — | WO | disclosed |
| US-20070259956-A1 | Compositions and methods for treating cancer | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2007-11-08 | — | — | US | disclosed |
| US-20060247302-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | FASGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| US-20060241177-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | FAS SECURED CREDITORS HOLDCO, LLC | 2006-10-26 | — | — | US | disclosed |
| EP-1626711-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The Trustees of The University of Pennsylvania (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100885-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-0651636-B1 | CHEMOTHERAPY FOR CANCER | UNIV JOHNS HOPKINS (US) | 2002-10-02 | — | — | EP | disclosed |
| US-5759837-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | JOHN HOPKINS UNIVERSITY (US) | 1998-06-02 | — | — | US | disclosed |
| US-5614551-A | Inhibitors of fatty acid synthesis as antimicrobial agents | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040052-B2 | Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof | BECN1, ATG7, SQSTM1 | CHAT 947/4885NAA50 1651/4885EP300 1400/4885 |
| US-20190008884-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | BECN1, SQSTM1, ATG7 | CHAT 688/4885NAA50 1767/4885EP300 1204/4885 |
| US-20210030703-A1 | USE OF CALORIC RESTRICTION MIMETICS FOR POTENTIATING CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF CANCERS | CD274, PDCD1, PDCD10 | CHAT 2714/4885NAA50 2284/4885EP300 195/4885 |
| US-20060241177-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | CPT1B, CPT1A, CRAT | CHAT 795/4885NAA50 474/4885EP300 161/4885 |
| US-20060247302-A1 | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | CPT1B, HCRTR2, CPT1A | CHAT 292/4885NAA50 391/4885EP300 648/4885 |
| US-20160250249-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOF | BECN1, ATG7, SQSTM1 | CHAT 947/4885NAA50 1651/4885EP300 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.